Lonza Group AG (SWX: LONN)

https://www.lonza.com

Twitter: @LonzaGroup

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens. Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma & Biotech and Specialty Ingredients. *

	Start	1999-11-01 splitoff
	Group	Lonza (Group)
	Today	Lonza (Group)
	Industry	fine chemicals
	Person	Funk, Marc (Lonza 201903–202001 CEO before COO of Pharma+Biotech division joined Lonza 1/09 LEFT 1/20)
	Person 2	Savitzky, Rodolfo (Lonza 201801 CFO)

	Region	Basel BS
	Country	Switzerland
	Street	38 Münchensteiner Str.
	City	4002 Basel BS
	Tel	+41-61-316-8111
		Address record changed: 2020-12-02

Basic data	Employees	H: 10,001 to 50,00 (2017-12-31)
	Currency	CHF
	Annual sales	5,105,000,000 (sales, consolidated (2017) 2017-12-31)
	Profit	728,000,000 (2017-12-31)
	Cash	479,000,000 (2017-12-31)

		* Document for ï¿½About Sectionï¿½: Lonza Group Ltd.. (10/30/14). "Press Release: Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement". New York, NY & Basel.

		Record changed: 2021-01-20